Eisai

Focus: Alzheimer’s Disease/Dementia, Sleep – Wake Rhythm Disorder, Epilepsy

Tokyo based, family-owned, and deeply entrepreneurial, Eisai focuses its efforts on areas of unmet patient needs. As a result, we currently have 18 compounds in clinical development across neurology and oncology. Each has a unique mechanism of action and are first to market compounds in their space.

Pharmaceutical Companies